Tempus AI, Inc. (TEM) shares declined Monday, even as the company celebrated a significant achievement from its wholly owned subsidiary. Ambry Genetics announced it has completed its one-millionth DNA and RNA test, underscoring growing market acceptance of RNA-informed diagnostics for hereditary cancer and rare disease screening.

The RNA Testing Breakthrough

Ambry Genetics brought RNA testing to market in 2019 under the +RNAinsight brand. The numbers tell a compelling story: analysis of over 450,000 patients revealed that incorporating RNA data identifies 1 in 25 positive patients who would have been missed using DNA testing alone. Additionally, RNA inclusion reduced variants classified as uncertain by 6%, helping doctors and patients get clearer answers.

The company expanded its RNA testing capabilities in 2024, adding the technology to its ExomeReveal offering for rare disease cases.

Technical Picture Shows Bearish Signals

Tempus AI is currently trading 11.4% below its 20-day simple moving average and 23% below its 100-day SMA, pointing to bearish momentum in both the short and medium term. Over the past 12 months, shares have dropped 2.79% and are sitting closer to their 52-week lows than highs.

The technical indicators paint a mixed picture. The RSI sits at 37.98, which is neutral territory, while the MACD remains below its signal line, suggesting continued bearish pressure. It's a combination that indicates uncertain momentum ahead.

• Key Resistance: $66.00
• Key Support: $59.00

What Wall Street Expects

Investors are eyeing the next earnings report scheduled for Feb. 23. Analysts are projecting:

• EPS Estimate: Loss of 14 cents (improvement from loss of 18 cents year-over-year)
• Revenue Estimate: $364.25 million (up from $200.68 million year-over-year)

Analyst Consensus & Recent Actions:

The stock holds a Buy rating with an average price target of $77.86. Recent analyst activity includes:

• Canaccord Genuity: Buy (Lowers Target to $80.00) (Dec. 22, 2025)
• JP Morgan: Neutral (Lowers Target to $80.00) (Dec. 15, 2025)
• Morgan Stanley: Overweight (Raises Target to $85.00) (Dec. 2, 2025)

Performance Snapshot

Looking at Tempus AI's market performance metrics:

• Momentum: Weak (Score: 46.6) — The stock is underperforming the broader market.

Monday's Price Action

TEM Price Action: Tempus AI shares were down 1.60% at $58.86 during premarket trading on Monday.